These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: an opportunity to revisit urology clinical guidelines. Pivovarcikova K; Pitra T; Alaghehbandan R; Buchova K; Steiner P; Hajkova V; Ptakova N; Subrt I; Skopal J; Svajdler P; Farcas M; Slisarenko M; Michalova K; Strakova Peterikova A; Hora M; Michal M; Daum O; Svajdler M; Hes O Virchows Arch; 2023 Oct; 483(4):517-526. PubMed ID: 37612527 [TBL] [Abstract][Full Text] [Related]
5. Variable Expression of MSH6 in Endometrial Carcinomas With Intact Mismatch Repair and With MLH1 Loss Due to MLH1 Methylation. Tandon N; Hudgens C; Fellman B; Tetzlaff MT; Broaddus RR Int J Gynecol Pathol; 2020 Nov; 39(6):507-513. PubMed ID: 31855955 [TBL] [Abstract][Full Text] [Related]
6. Universal screening for Lynch syndrome in operated colorectal cancer by immunohistochemistry: a cohort of patients in Liaoning province, China. Zhao G; Xiang G; Hu X; Qiao Y; Ma S; Tian Y; Gao X; Liu F; Li X; Shi G Eur J Cancer Prev; 2023 Jul; 32(4):337-347. PubMed ID: 36942852 [TBL] [Abstract][Full Text] [Related]
7. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome. Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236 [TBL] [Abstract][Full Text] [Related]
8. Assessing Mismatch Repair Expression by Immunohistochemistry in Colorectal Adenocarcinoma -Insight from a Tertiary Care Centre. Lakhe R; Doshi R; Doshi P; Patil A; Nimbargi R Gulf J Oncolog; 2024 May; 1(45):35-41. PubMed ID: 38774931 [TBL] [Abstract][Full Text] [Related]
9. Mismatch Repair Protein Deficiency Does Not Affect Disease Free Survival in Type I Endometrial Carcinoma. Angelina YA; Tjokroprawiro BA; Sandhika W Asian Pac J Cancer Prev; 2023 Sep; 24(9):3229-3234. PubMed ID: 37774076 [TBL] [Abstract][Full Text] [Related]
10. Predicting Mismatch Repair Deficiency Status in Endometrial Cancer through Multi-Resolution Ensemble Learning in Digital Pathology. Whangbo J; Lee YS; Kim YJ; Kim J; Kim KG J Imaging Inform Med; 2024 Aug; 37(4):1674-1682. PubMed ID: 38378964 [TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome: toward an increasingly complex picture. The case of PMS2. Calvello M; Bonanni B Eur J Cancer Prev; 2023 Sep; 32(5):413-414. PubMed ID: 36942845 [No Abstract] [Full Text] [Related]
12. Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations. Khushman MM; Toboni MD; Xiu J; Manne U; Farrell A; Lou E; Shields AF; Philip PA; Salem ME; Abraham J; Spetzler D; Marshall J; Jayachandran P; Hall MJ; Lenz HJ; Sahin IH; Seeber A; Powell MA Clin Cancer Res; 2024 May; 30(9):1906-1915. PubMed ID: 38350001 [TBL] [Abstract][Full Text] [Related]
13. Novel MSH2 and TSC2 variants in a Chinese family with Lynch syndrome and their synergistic impact in urothelial carcinoma. Li M; Yan X; Liu H; Miao W; Wu W; Zhao Y; Wang C; Liu H Transl Res; 2024 Mar; 265():26-35. PubMed ID: 37914149 [TBL] [Abstract][Full Text] [Related]
14. A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma. Gabriel PE; Cancel-Tassin G; Audenet F; Masson-Lecomte A; Allory Y; Roumiguié M; Pradère B; Loriot Y; Léon P; Traxer O; Xylinas E; Rouprêt M; Neuzillet Y; Seisen T BJU Int; 2024 May; ():. PubMed ID: 38813615 [TBL] [Abstract][Full Text] [Related]
16. Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening. Li Z; Xu H; Gong Y; Chen W; Zhan Y; Yu L; Sun Y; Li A; He S; Guan B; Wu Y; Xiong G; Fang D; He Y; Tang Q; Yao L; Hu Z; Mei H; He Z; Cai Z; Guo Y; Li X; Zhou L; Huang W Adv Sci (Weinh); 2022 Feb; 9(4):e2103999. PubMed ID: 34914855 [TBL] [Abstract][Full Text] [Related]
17. The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. Soualhi A; Rammant E; George G; Russell B; Enting D; Nair R; Van Hemelrijck M; Bosco C BMC Urol; 2021 Aug; 21(1):110. PubMed ID: 34404373 [TBL] [Abstract][Full Text] [Related]
18. A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancer. Hill AL; Sumra KK; Russell MM; Yoo J; Ko CY; Hart S; Wainberg Z; Hecht JR; Lin AY J Gastrointest Surg; 2015 Mar; 19(3):543-50. PubMed ID: 25504462 [TBL] [Abstract][Full Text] [Related]
19. Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting. Grillo F; Angerilli V; Parente P; Vanoli A; Luchini C; Sciallero S; Puccini A; Bergamo F; Lonardi S; Valeri N; Mastracci L; Fassan M Virchows Arch; 2024 Jan; ():. PubMed ID: 38231403 [No Abstract] [Full Text] [Related]
20. Lynch Syndrome: Its Impact on Urothelial Carcinoma. Lindner AK; Schachtner G; Tulchiner G; Thurnher M; Untergasser G; Obrist P; Pipp I; Steinkohl F; Horninger W; Culig Z; Pichler R Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]